A multidisciplinary training program in prostate cancer

前列腺癌是美国男性癌症相关死亡的第二大原因， 预计2018年约有29，000人死亡。它最初对雄激素消融有反应，但最终 进展到称为转移性去势抵抗性前列腺癌的更晚期的疾病状态。那里 目前有六种FDA批准的mCRPC疗法，每种疗法均可延长生存期约2-4 个月然而，每年有近165，000名男性被诊断出患有这种疾病， 在美国，管理生活质量和疾病进展风险是需要关注的未解决问题。的 塞达斯-西奈医学中心的塞缪尔·奥斯钦综合癌症研究所（SOCCI）治疗最高的 西海岸癌症患者的数量。研究发现的翻译有助于更有效地 诊断、治疗和预防多种形式癌症的方法是SOCCI的核心使命。14教师 （小学和中学）致力于培养前列腺癌1）生物学，2）临床 3）卫生服务研究有助于机构对高水平癌症患者的承诺 在乎作为证据，88%的受训者（博士）（M.D.）在过去五年里离开这个项目的人 学术研究或制药行业。将实验室科学转化为临床试验， 从临床观察中发展实验假设来自与 临床医生/外科医生-科学家。所有学员将参与负责任的行为研究，赠款写作， 交流讲习班、生物统计单元以及定期会议和研讨会沿着。平均而言， 4.6新的培训补助金合格（TGE）博士后研究员每年可用于前列腺癌培训 计划教师;我们正在申请1-2年的一名新博士后培训生和2名新博士后培训生的资金支持。 研究员在3-5年，以培养前列腺癌合作研究的领导者，以促进更好的病人护理。 南加州的人口和与代表性不足的少数民族研究生课程的相互作用 全国各地都是申请人的一部分。在过去的五年里，25%的TGE博士后 参加该方案的候选人是代表性不足的少数族裔。这款新的T32应用程序计划严格 研究培训，个性化的职业发展，以及密切的指导，以满足年轻人的需求 研究人员和癌症患者护理。

Prostate cancer is the second leading cause of cancer related death in men in the United States, with approximately 29,000 deaths projected for 2018. It is initially responsive to androgen-ablation, but eventually progresses to a more advanced disease state known as metastatic castration-resistant prostate cancer. There are currently six FDA-approved therapies for mCRPC each of which extends survival by approximately 2-4 months. However, with nearly 165,000 men diagnosed yearly and over a million living with the disease in the US, managing quality of life and risk of progression of the disease are unmet concerns that need attention. The Samuel Oschin Comprehensive Cancer Institute (SOCCI) at Cedars-Sinai Medical Center treat the highest volume of cancer patient on the west coast. The translation of research discoveries contributing to more effective ways to diagnose, treat, and prevent many forms of cancer is a core mission of the SOCCI. The 14 faculty (primary and secondary) dedicated to training PhD, MD, and MD/PhD in prostate cancer 1) biology, 2) clinical trial, and 3) health services research contribute to the institutional commitment to high level of cancer patient care. As evidence, 88% of the trainees (Ph.D. and M.D.) that left the program in the past five years are doing research in academics or pharmaceutical industry. The translation of the bench science to clinical trials and development of experimental hypothesizes from clinical observations is derived from collaborations with clinician/surgeon-scientists. All trainees will participate in responsible conduct in research, grant writing and communication workshops, and biostatistics modules along with regular conferences and seminars. On average, 4.6 new training grant eligible (TGE) postdoctoral fellows are available yearly to the Prostate Cancer Training Program faculty; we are requesting funding support for one new postdoctoral trainee in years 1-2 and two new fellows in years 3-5 to develop leaders in collaborative prostate cancer research to promote better patient care. The population of southern California and interactions with underrepresented minority graduate programs throughout the country are part of the applicant pool. In the past five years, 25% of the TGE postdoctoral candidates that joined the program were underrepresented minority. This new T32 application plans for rigorous research training, personalized career development, and close mentorship to address the needs of young investigators and cancer patient care.